Supriya Lifescience IPO GMP History
Supriya Lifescience IPO has been listed on December 28, 2021 at a listing price of ₹421, against the issue price of ₹274 — a gain of ₹147 (+53.65%). The GMP peaked at ₹400 on 10 December 2021 and reached a low of ₹130 on 23 December 2021. The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Supriya Lifescience IPO raised ₹700 Cr. through its IPO at a price band of ₹265 to ₹274 per share, with a lot size of 54 shares. The IPO was open for subscription from 16 Dec 2021 to 20 Dec 2021.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
GMP trend
Grey market premium sampled three times a day (11 AM, 5 PM, 10 PM). Last updated 10 Nov, 7:27 AM IST.
Day-wise GMP
The last reading of each day, newest first. Arrows compare with the previous day.
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| 28 Dec 2021 | ₹ 140 | — | 51% | — | — |
| 27 Dec 2021 | ₹ 140 | — | 51% | — | — |
| 26 Dec 2021 | ₹ 140 | — | 51% | — | — |
| 25 Dec 2021 | ₹ 140 | — | 51% | — | — |
| 24 Dec 2021 | ₹ 140 | ▲ | 51% | — | — |
| 23 Dec 2021 | ₹ 130 | — | 47% | — | — |
| 22 Dec 2021 | ₹ 130 | — | 47% | — | — |
| 21 Dec 2021 | ₹ 130 | ▼ | 47% | — | — |
| 20 Dec 2021 | ₹ 180 | — | 66% | — | — |
| 19 Dec 2021 | ₹ 180 | ▼ | 66% | — | — |
| 18 Dec 2021 | ₹ 280 | — | 102% | — | — |
| 17 Dec 2021 | ₹ 280 | ▲ | 102% | — | — |
| 16 Dec 2021 | ₹ 250 | — | 91% | — | — |
| 15 Dec 2021 | ₹ 250 | — | 91% | — | — |
| 14 Dec 2021 | ₹ 250 | ▼ | 91% | — | — |
| 10 Dec 2021 | ₹ 400 | ▲ | 146% | — | — |
| 09 Dec 2021 | ₹ 250 | — | 91% | — | — |
Supriya Lifescience IPO dates
Key dates from opening to listing. Today is 11 November.
- Open 16 Dec 2021
- Close 20 Dec 2021
- Allotment 23 Dec 2021
- Refund/credit 24 Dec 2021
- Listing 28 Dec 2021
Supriya Lifescience IPO actual listing price
How the grey market's final call compared with the listing-day open.
| Issue price | ₹274 |
|---|---|
| GMP-based estimate (pre-listing) | ₹524 (+91.2%) |
| Listing gain / loss | +₹147 per share |
| Listing date | 28 Dec, 2021 |
| Actual listing price | ₹421 (+53.65%) |
Is Supriya Lifescience IPO GMP reliable?
Grey market premium for Supriya Lifescience IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- 01Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- 02Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- 03Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- 04Cross-check before acting: Review the Supriya Lifescience IPO full review for a fundamentals-based assessment before making any grey market trades.
Supriya Lifescience IPO Kostak rate explained
Two ways the grey market trades an IPO application before listing.
The Kostak rate for Supriya Lifescience IPO was not available during the subscription period. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not available for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Supriya Lifescience IPO
Supriya Lifescience Limited is one of the key Indian makers and suppliers of APIs, with a focus on research and development. On 31 October 2021 it offered 38 APIs for antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic uses.
It was consistently the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India between Fiscal 2017 and 2021, with 45-50% and 60-65% of India's exports of those APIs. It also had 31% of India's Salbutamol Sulphate exports by volume in FY 2021.
From 1 April 2020 to 31 October 2021 it exported to 86 countries and 1,296 customers, including 346 distributors. Its plant in Maharashtra covers 23,806 sq. mts and has reactor capacity of 547 KL a day.
The IPO was Rs 700 crore, with Rs 200.00 crore of fresh issue and Rs 500.00 crore of offer for sale by the promoter Satish Waman Wagh. Rs 92.30 crore was planned for capital expenditure and Rs 60.00 crore for repaying borrowings.
Frequently asked
What is the GMP of Supriya Lifescience IPO?
The current Grey Market Premium (GMP) of Supriya Lifescience IPO is ₹ 250.
What is the Kostak Price of Supriya Lifescience IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Supriya Lifescience IPO is not available.
What is the Subject to Sauda Price of Supriya Lifescience IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is not available.
What was the actual listing price of Supriya Lifescience IPO?
Supriya Lifescience IPO listed on December 28, 2021 at ₹421, against the issue price of ₹274 — a gain of +53.65%.
How did the GMP of Supriya Lifescience IPO trend before listing?
The GMP of Supriya Lifescience IPO was stable in its final days before listing. The GMP peaked at ₹400 on 10 December 2021. View the day-wise table above for the complete GMP history.
Explore Supriya Lifescience IPO further
The grey market is one signal. Read it alongside the demand, the reviews and the filings before you decide.
It has listed — go back to the fundamentals.
Category-wise demand from QIB, NII and retail investors, updated through the day.
What brokers and analysts are saying about this issue, in one place.
Check with your PAN whether shares were credited to your demat account.
The grey market called it. Now check the fundamentals.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Read the grey market alongside the subscription book and the offer document before you apply.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
